Sabeluzole

Sabeluzole is a neuroprotective agent which was under investigation for the treatment of Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It was developed by the Belgian pharmaceutical company Janssen Pharmaceutica.

Mechanism of Action

Sabeluzole acts by modulating glutamate transmission, thereby reducing the excitotoxicity which is believed to be a major factor in the death of nerve cells in ALS. It is thought to work by blocking the action of glutamate at the NMDA receptor, although the exact mechanism is not fully understood.

Clinical Trials

Sabeluzole has been tested in several clinical trials for ALS. In a phase II trial, it was found to have a positive effect on survival, but this was not confirmed in a larger phase III trial. The drug was generally well tolerated, with the most common side effects being nausea and dizziness.

Current Status

As of 2021, sabeluzole is not approved for use in any country. The development of the drug was discontinued after the phase III trial failed to show a significant benefit in terms of survival or functional outcomes.

See Also

• Neuroprotection
• Amyotrophic lateral sclerosis
• Glutamate
• NMDA receptor

References

Sabeluzole Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski